Your browser is no longer supported. Please, upgrade your browser.
Settings
ORGS Orgenesis Inc. daily Stock Chart
ORGS [NASD]
Orgenesis Inc.
Index- P/E- EPS (ttm)-1.42 Insider Own26.45% Shs Outstand16.52M Perf Week-2.74%
Market Cap70.38M Forward P/E- EPS next Y- Insider Trans- Shs Float11.98M Perf Month-2.52%
Income-21.00M PEG- EPS next Q-0.29 Inst Own4.20% Short Float1.17% Perf Quarter-15.64%
Sales23.30M P/S3.02 EPS this Y-7.00% Inst Trans0.43% Short Ratio4.97 Perf Half Y-13.59%
Book/sh1.33 P/B3.20 EPS next Y- ROA-30.40% Target Price10.00 Perf Year-49.10%
Cash/sh0.87 P/C4.89 EPS next 5Y- ROE-80.30% 52W Range3.78 - 9.25 Perf YTD-8.97%
Dividend- P/FCF- EPS past 5Y-0.80% ROI-61.80% 52W High-53.95% Beta1.27
Dividend %- Quick Ratio1.00 Sales past 5Y- Gross Margin42.00% 52W Low12.70% ATR0.26
Employees231 Current Ratio1.10 Sales Q/Q180.80% Oper. Margin- RSI (14)48.51 Volatility3.56% 5.66%
OptionableNo Debt/Eq0.22 EPS Q/Q-2.50% Profit Margin-90.00% Rel Volume0.63 Prev Close4.18
ShortableYes LT Debt/Eq0.16 EarningsJul 23 Payout- Avg Volume28.27K Price4.26
Recom2.00 SMA20-0.65% SMA50-1.59% SMA200-15.75% Volume17,712 Change1.91%
Dec-20-18Initiated Dawson James Buy
Jun-17-19 08:41AM  U.S. stocks set to rise cautiously as Federal Reserve gathering comes into focus MarketWatch
07:46AM  Orgenesis shares soar 19% premarket after FDA grants orphan designation to insulin tech MarketWatch
07:00AM  Orgenesis Granted FDA Orphan Drug Designation for Autologous Insulin Producing Cells in the Treatment of Severe Hypoglycemia-Prone Diabetes Resulting from Total Pancreatectomy GlobeNewswire
May-09-19 09:00AM  Orgenesis First Quarter 2019 Revenue Increases 177% to a Record $7.3 Million GlobeNewswire
Apr-30-19 09:00AM  Orgenesis Announces Planned Study to Confirm Suitability of Liver Cells as a Source for Personalized Cell Replacement Therapy for Insulin-Dependent Diabetic Patients GlobeNewswire +5.87%
Apr-24-19 11:01AM  Those Who Purchased Orgenesis (NASDAQ:ORGS) Shares A Year Ago Have A 53% Loss To Show For It Simply Wall St.
Apr-23-19 08:30AM  MicroCap Review Magazine Spring 2019 Issue Now Available ACCESSWIRE
Apr-22-19 09:00AM  Orgenesis Announces Collaboration Agreement with Columbia University to Develop Cellular Vaccination Product Platform for Pancreatic, Hepatic and Cholangiocarcinoma Cancers GlobeNewswire
Apr-11-19 09:00AM  Orgenesis Announces Collaboration and License Agreement for Exosome-Related Technologies with ExcellaBio GlobeNewswire
Apr-08-19 10:30AM  Will Orgenesis Inc. (ORGS) Report Negative Q1 Earnings? What You Should Know Zacks
Apr-04-19 09:42AM  Orgenesis Announces Collaboration with Digilab to Develop Industrial 3D Printing Capability for Cellular Structures and Tissues for Clinical Use GlobeNewswire
Apr-03-19 09:00AM  Orgenesis Announces Publication of an Independent Study The Role of The Vasculature Niche on Insulin Producing Cells Generated by Transdifferentiation of Adult Human Liver Cells in the Stem Cell Research and Therapy Journal GlobeNewswire
Mar-28-19 09:00AM  Orgenesis Signs Master Service and Joint Venture Agreement with TheraCell Advanced Biotechnology for the Development of Cell and Gene Therapies GlobeNewswire
Mar-27-19 08:30AM  Orgenesis Inc. Provides 2018 Corporate Highlights, Clinical Development and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com ACCESSWIRE
Mar-25-19 09:18AM  Orgenesis Subsidiary Masthercell Global Announces Plans to Establish New Facility for Cell and Gene Therapy Commercial Manufacturing GlobeNewswire +8.60%
Mar-07-19 11:31AM  Does Orgenesis Inc.s (NASDAQ:ORGS) CEO Pay Compare Well With Peers? Simply Wall St.
Feb-14-19 08:44AM  Orgenesis Reports 85% Increase in Revenue and 139% Increase in Gross Profit for Fiscal 2018 GlobeNewswire
Feb-11-19 08:30AM  Orgenesis CEO to Participate in Panel at the 2019 BIO CEO & Investor Conference GlobeNewswire
Feb-06-19 08:30AM  Orgenesis CSO Sara Ferber to Present to the International Research Training Group Hosted by Technische Universität Dresden and the King's College London GlobeNewswire
Feb-05-19 08:30AM  Orgenesis Announces the Opening of New Offices and Laboratories at Accessia Pharma in Liège, Belgium to Support its Point of Care Cellular Therapy Platform GlobeNewswire
Jan-25-19 08:30AM  Orgenesis Announces U.S. Expansion of Masthercell Global Subsidiary GlobeNewswire
Jan-22-19 04:00PM  Penny Stocks to Buy Using Technical Analysis for January 2019 Investopedia
11:57AM  Orgenesis Subsidiary Atvio Biotech to Present at Phacilitate Leaders World 2019 Conference GlobeNewswire
Jan-03-19 08:30AM  Orgenesis CEO Selected to Participate in Cell and Gene Therapy Workshop at Biotech Showcase 2019 in California GlobeNewswire -6.61%
Dec-31-18 07:35AM  Analysis: Positioning to Benefit within PPL, Inseego, Scientific Games, Orgenesis, CUI Global, and TRACON Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Dec-18-18 01:30PM  Orgenesis Announces Collaboration with MangoGen Pharma for Advanced Gene Delivery Platform GlobeNewswire
Dec-13-18 06:21AM  Orgenesis CEO Vered Caplan to Appear on Fox Business Networks Mornings with Maria GlobeNewswire
Dec-12-18 01:47PM  Orgenesis CEO Vered Caplan to Present at William Blairs Biotech Focus Day Series: Cell and Gene Therapy Manufacturing GlobeNewswire
08:30AM  Orgenesis Announces Collaboration with Ben-Gurion University to Research and Develop Dissolvable Carriers for Cell Culturing GlobeNewswire
Dec-04-18 12:30AM  Orgenesis Announces that Dr. Ohad Karnieli, CEO of Atvio Biotech, a Wholly-Owned Subsidiary of Masthercell Global, will Present at the Cell Therapy Manufacturing & Gene Therapy Congress GlobeNewswire
Nov-30-18 08:30AM  Orgenesis Subsidiary Masthercell Global Expands Production and Doubles its Capacity GlobeNewswire
Nov-21-18 08:30AM  Orgenesis Announces Collaboration with the New York Blood Center for Tissue Collection, Processing and Biobanking U.S. Cell Therapy Development Program GlobeNewswire
Nov-19-18 08:50AM  Detailed Research: Economic Perspectives on Miller Industries, P & F Industries, Schmitt Industries, Orgenesis, AMERI, and TrovaGene What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-15-18 09:45AM  How Does Orgenesis Inc (NASDAQ:ORGS) Affect Your Portfolio Volatility? Simply Wall St.
Nov-02-18 01:24PM  How Orgenesis is breaking barriers in biotech Yahoo Finance Video
11:58AM  Orgenesis CEO Vered Caplan to Appear Live Today on Midday Movers on Yahoo Finance GlobeNewswire
Oct-23-18 08:30AM  Orgenesis to Present at Dawson James Securities 4th Annual Small Cap Growth Conference GlobeNewswire
Oct-22-18 08:30AM  Orgenesis Announces Collaboration with Hemogenyx to Develop Blood Stem Cell Replacement Product GlobeNewswire
Oct-19-18 09:00AM  Orgenesis Announces Collaboration with Immugenyx to Develop and Commercialize Advanced Hematopoietic Chimeras GlobeNewswire
Oct-18-18 01:00PM  Orgenesis CEO to Participate in Panel Presentation at The Cellular Living Drug Revolution Summit in New York City GlobeNewswire
08:30AM  Orgenesis Subsidiary Masthercell Global Announces Manufacturing Services Agreement with Iovance Biotherapeutics in Europe GlobeNewswire
07:00AM  Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe GlobeNewswire
Oct-15-18 08:30AM  Orgenesis Reports 143% Increase in Revenue and 316% Increase in Gross Profit for the Third Quarter of Fiscal 2018 GlobeNewswire
Oct-11-18 01:57PM  Orgenesis to Provide Keynote Address and Poster Presentation at the 2018 International Conference on Diabetes and Endocrinology GlobeNewswire -5.40%
Oct-04-18 10:42AM  Orgenesis Announces License Agreement with HekaBio in Japan GlobeNewswire
Oct-01-18 08:30AM  Kangstem Biotech Selects Orgenesis Subsidiary Masthercell for GMP Manufacturing of Furestem-AD© in Europe GlobeNewswire
Sep-28-18 08:30AM  Orgenesis Announces Poster Presentation at the 54th Annual Meeting of the European Association of the Study of Diabetes GlobeNewswire
Aug-23-18 07:30AM  Orgenesis Announces Collaboration with Ben-Gurion University to Develop and Commercialize a Novel Scaffold Technology for Cell Transplantation GlobeNewswire
Aug-15-18 08:30AM  Orgenesis Announces that Dr. Ohad Karnieli, CEO of Atvio Biotech, a Wholly-Owned Subsidiary of Masthercell Global, will Present at the 2018 Bioprocessing Summit GlobeNewswire
Jul-30-18 08:30AM  Orgenesis Announces Collaboration between Secant Group and Atvio Biotech, a Wholly Owned Subsidiary of Masthercell Global, to Develop and Commercialize Scaffold Technologies for Advanced Cell Therapies GlobeNewswire +6.97%
Jul-20-18 07:00AM  Wired News Biogen to Present Data from Alzheimers Disease Clinical Development Portfolio at AAIC in Chicago ACCESSWIRE
Jul-17-18 10:53AM  Orgenesis Reports 73% Increase in Revenue for the Second Quarter of Fiscal 2018 GlobeNewswire
Jun-29-18 01:22PM  [$$] Great Point to Back Subsidiary of Publicly Traded Orgenesis The Wall Street Journal
07:30AM  Orgenesis Forms Strategic Partnership with Leading Healthcare Fund and Reports Planned Investment of up to $25 Million into MaSTherCell Subsidiary GlobeNewswire
Jun-25-18 09:12AM  Orgenesis Inc. Added to Russell Microcap® Index GlobeNewswire
Jun-04-18 09:06PM  Who Are The Largest Shareholders In Orgenesis Inc (NASDAQ:ORGS)? Simply Wall St.
12:20PM  Orgenesis CDMO Partner Atvio Biotechnologys CEO to Present on Roundtable at the 2018 BIO International Convention GlobeNewswire
May-17-18 04:59PM  How Does Investing In Orgenesis Inc (NASDAQ:ORGS) Impact Your Portfolio? Simply Wall St.
May-16-18 01:19AM  Orgenesis and Atvio Biotechnology to Present at the World Advanced Therapies & Regenerative Medicine Congress GlobeNewswire
Apr-30-18 08:30AM  Orgenesis Appoints Professor Lorenzo Piemonti to Scientific Advisory Board GlobeNewswire
Apr-19-18 10:03AM  Orgenesis Reports 42% Increase in Revenue for the First Quarter of Fiscal 2018 GlobeNewswire
Apr-13-18 09:03AM  Does Orgenesis Incs (NASDAQ:ORGS) CEO Pay Compare Well With Peers? Simply Wall St.
Mar-22-18 01:28PM  Where Orgenesis Incs (NASDAQ:ORGS) Earnings Growth Stands Against Its Industry Simply Wall St.
Mar-19-18 08:30AM  MaSTherCell Appointed as Process Development and Manufacturing Partner for Zelluna Immunotherapys TCR Adoptive Cell Therapy Platform GlobeNewswire -11.19%
Mar-12-18 08:30AM  Orgenesis Announces Listing on NASDAQ Capital Market GlobeNewswire
Mar-05-18 07:00AM  Orgenesis Reports 78% Increase in Revenue for the Fourth Quarter of Fiscal 2017 GlobeNewswire
Feb-06-18 09:00AM  Orgenesis and Adva Biotechnology to Develop and Distribute Advanced Automated Culturing System for Cell Therapy Manufacturing GlobeNewswire
Oct-18-17 06:00AM  Orgenesis to Present at BIO Investor Forum Marketwired
Oct-17-17 08:37AM  Orgenesis, Inc. :ORGS-US: Earnings Analysis: Q3, 2017 By the Numbers : October 17, 2017 Capital Cube
Aug-21-17 10:30AM  Diamond Equity Research Initiates Coverage On Orgenesis Inc. (OTCQB: ORGS) ACCESSWIRE
Jun-12-17 08:00AM  Orgenesis to Present at the 2017 Marcum MicroCap Conference Marketwired +14.64%
Orgenesis Inc., a biotechnology company, engages in the development, manufacturing, and provision of services in the cell and gene therapy industry. The CDMO segment specializes in therapy development services, such as manufacturing and development services, and contract manufacturing services. The PT Business segment focuses on the development of proprietary cell and gene therapies, including the autologous trans-differentiation technology. It also has various collaboration and license agreements with Adva Biotechnology Ltd.; Tel Hashomer Medical Research, Infrastructure and Services Ltd; Mircod Limited; HekaBio K.K; Image Securities Ltd.; Hemogenyx Pharmaceuticals PLC.; Immugenyx LLC.; BG Negev Technologies and Applications; and Columbia University. The company was formerly known as Business Outsourcing Services, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.